NDA 018484 · Pfizer
Prostin Vr Pediatric
Alprostadil · Injection · Prostaglandin Analog; Prostaglandin E1 Agonist
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Oct 16, 1981
Approved uses
2
Original approval plus efficacy supplements
Registered trials
145
40 Phase 3, 8 recruiting
FAERS reports
1,585
1,454 serious, 228 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING Apnea is experienced by about 10 to 12% of neonates with congenital heart defects treated with PROSTIN VR PEDIATRIC Sterile Solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, respiratory status should be monitored throughout treatment, and PROSTIN VR PEDIATRIC should be used where ventilatory assistance is immediately available.
What it is approved for
From the label in effect Aug 17, 2026.
INDICATIONS AND USAGE PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 10, 1987 Supplement 5 · Efficacy
- Oct 16, 1981 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- PROSTIN VR PEDIATRIC · ALPROSTADIL 0.5MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Alprostadil" as an intervention, any sponsor and status, largest first.
- Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of LaborPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00308711 · 1,308 participants · Start Apr 2006 · Primary completion Aug 2007
Drug: Misoprostol vaginal insert 100 mcg; Misoprostol vaginal insert 50 mcg and 1 more · For: Cervical Ripening; Labor, Induced
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 52 sites in all
- Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic StrokePivotal-lookingStatus unknown
The First Hospital of Jilin UniversityAcademic, hospital or other
NCT03252626 · 950 participants (planned) · Start Apr 18, 2024 · Primary completion Dec 31, 2024
Drug: Alprostadil; Normal saline · For: Stroke
- Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic ConstipationPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01674530 · 909 participants · Start Oct 2012 · Primary completion Jan 2014
Drug: Lubiprostone; Lubiprostone and 1 more · For: Chronic Idiopathic Constipation
Sites: Birmingham, Alabama; Dothan, Alabama; Huntsville, Alabama · 93 sites in all
- Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IVPivotal-lookingCompleted
NCT00596752 · 840 participants · Start Mar 2004 · Primary completion May 2013
Drug: Alprostadil · For: Peripheral Arterial Occlusive Disease
Sites: Pilsen, Czechia; Ústí nad Labem, Czechia; Karlsbad, Germany · 78 sites in all
- Evaluation of Clinical Equivalence Between Two Lubiprostone ProductsPivotal-lookingCompleted
Anchen Pharmaceuticals, IncIndustry
NCT01372423 · 808 participants · Start May 2011 · Primary completion Jun 2012
Drug: Lubiprostone; Placebo · For: Chronic Idiopathic Constipation
Sites: Dothan, Alabama; Huntsville, Alabama; Mobile, Alabama · 79 sites in all
- Labor Induction and Maternal BMI, Comparison of Different Pre-induction Cervical Ripening MethodsPivotal-lookingStatus unknown
Hillel Yaffe Medical CenterGovernment (non-federal)
NCT02223949 · 624 participants (planned) · Start Oct 2014 · Primary completion Oct 2016
Drug: PGE1 tablet · For: Obesity; Labor Complications
Sites: Hadera, Israel
- Lubiprostone in Children With Functional ConstipationPivotal-lookingCompleted
Sucampo Pharma Americas, LLCIndustry
NCT02042183 · 606 participants · Start Dec 13, 2013 · Primary completion Jul 27, 2016
Drug: Lubiprostone; Placebo · For: Constipation - Functional
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 117 sites in all
- ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart FailurePivotal-lookingNot yet recruiting
Biopeutics Co., LtdIndustry
NCT00610051 · 600 participants (planned) · Start Oct 2026 · Primary completion Nov 2029
Drug: Alprostadil · For: End Stage Cardiac Failure; HFrEF - Heart Failure With Reduced Ejection Fraction; NYHF Class III-IV
Sites: Vienna, Austria
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use126
- drug ineffective124
- haemoglobin decreased82
- lymphocyte count decreased79
- pyrexia77
- diarrhoea70
- cardiac failure64
- blood urea increased59
- condition aggravated55
- anaemia54
- blood glucose increased54
- neutrophil count increased54
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 48 |
| 2005 | 64 |
| 2006 | 72 |
| 2007 | 41 |
| 2008 | 62 |
| 2009 | 31 |
| 2010 | 53 |
| 2011 | 98 |
| 2012 | 66 |
| 2013 | 35 |
| 2014 | 17 |
| 2015 | 60 |
| 2016 | 107 |
| 2017 | 155 |
| 2018 | 94 |
| 2019 | 115 |
| 2020 | 84 |
| 2021 | 86 |
| 2022 | 60 |
| 2023 | 46 |
| 2024 | 74 |
| 2025 | 57 |
| 2026 | 59 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Erectile dysfunction.
Khera M, Goldstein I · BMJ Clin Evid 2011 · Systematic Review
- Alprostadil for hypertensive nephropathy: A systematic review and meta-analysis of randomized controlled trials.
Fu H, Hou W, Zhang Y, et al. · PLoS One 2022 · Meta-Analysis, Systematic Review
- The effect of topical and intraurethral alprostadil on erectile function: A systematic review and meta-analysis.
Papadopoulos I, Tishukov M, Sokolakis I, et al. · Andrology 2025 · Systematic Review, Meta-Analysis
- Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis.
Zhang JZ, Kang XJ, Gao Y, et al. · Sci Rep 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatment for Buerger's disease.
Cacione DG, Macedo CR, do Carmo Novaes F, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of Alprostadil in Preventing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis.
Xu H, Wang H, Zhang C, et al. · Angiology 2021 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.